Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

21 Dec 2015 07:00

RNS Number : 6572J
Fastnet Equity PLC
21 December 2015
 

21 December 2015

 

Fastnet Equity plc

("Fastnet" or the "Company")

Interim Results for the six months ended 30 September 2015

 

We are pleased to report on the progress of Fastnet Equity plc ("Fastnet" or the "Company") and present the unaudited interim results for the six month period ended 30 September 2015.

 

Operational Highlights

· Concluded detailed asset review of the Company's oil and gas portfolio in light of the rapidly deteriorating economic conditions in the oil and gas sector during the last year

· Transition from an Oil & Gas business to an investment company following the adoption of an investing policy to acquire companies or businesses in the healthcare sector which was approved by shareholders on 28 August 2015

· Post period end, the oil and gas subsidiaries were demerged into a separate company, Fastnet Hydrocarbons Limited, on 17 December 2015. Fastnet Hydrocarbons Limited is held in trust for the benefit of shareholders on the register of the Company as at the close of business on 16 December 2015

· Fastnet will no longer have any ongoing interest or further cost exposure in respect of oil and gas assets

 

Financial and Corporate Highlights

· US$15.5m cash balance at 30 September 2015 (US$16.8m at 31 March 2015, US$18.8m at 30 September 2014)

· Net loss for the period of US$1.5m (6 months to 31 March 2015: loss of US$39.7m, 6 months to 30 September 2014: loss of US$1.6m). The current period net loss comprises general and administrative costs of US$1.2m and exploration and evaluation costs expensed of US$0.3m

· Change of the functional currency of Company to Euros (€) with the cash balance of US$15.1m converted into €13.7m on 31 October 2015 at an FX rate of US$1:€0.905

· Cash balance of €13.6m as at 30 November 2015 prior to the grant of an unsecured 4 year term loan €660,000 to finance residual running of oil and gas assets

Cathal Friel, Non-Executive Chairman, commented:

 

"Following the recently announced demerger of our oil and gas assets the Company is well positioned to focus on identifying and assessing potential investment targets within the healthcare sector." 

 

 

For further information please contact:

Fastnet Equity plc

+353 (1) 644 0007

Cathal Friel, Non-Executive Chairman

 

 

 

Shore Capital

+44 (0) 20 7408 4090

(Nomad & Joint Broker)

 

Bidhi Bhoma, Edward Mansfield

 

 

 

 

 

Davy

+353 (1) 679 6363

(ESM Adviser & Joint Broker)

 

John Frain, Anthony Farrell

 

 

 

Camarco

+44 (0) 20 3757 4980

Billy Clegg / Zoe Moulton

 

 

 

 

 

Consolidated Statement of Comprehensive Income

For the six months ended 30 September 2015

 

 

Unaudited

Audited

Audited

 

 

6 months to

 30 September 2015

6 months to

 30 September 2014

12 months to 31 March

 2015

 

Note

US$'000

US$'000

US$'000

Continuing operations

 

 

 

 

Revenue

 

-

-

-

Operational costs

 

-

-

-

Gross loss

 

-

-

-

General and administrative costs

 

(1,177)

(1,651)

(3,196)

Impairment of exploration and evaluation assets

 

(308)

-

(36,593)

Other operating expenses

 

(4)

-

(12)

Share based payments

 

(30)

(74)

(129)

Operating loss

 

(1,519)

(1,725)

(39,930)

Finance income

 

50

95

185

Net foreign exchange gain

 

10

2

4

Loss on ordinary activities before taxation

 

(1,459)

(1,628)

(39,741)

Tax on loss on ordinary activities

 

-

-

-

Loss and total comprehensive loss for the period attributable to the equity holders of the Company

 

(1,459)

(1,628)

(39,741)

 

Loss per share:

 

 

 

 

 

Loss per share - basic and diluted, attributable to ordinary equity holders of the parent (cent)

 

3

 

(0.42)

 

-(0.47)

 

(11.51)

 

 

 

 

Consolidated Statement of Financial Position

As at 30 September 2015

 

Unaudited

30 September 2015

Unaudited

30 September 2014

Audited

31 March

 2015

 

US$'000

US$'000

US$'000

Assets

 

 

 

Non-current assets

 

 

 

Property, plant and equipment

5

11

8

Exploration and evaluation assets

-

35,986

-

Total non-current assets

5

35,997

8

 

 

 

 

Current assets

 

 

 

Trade and other receivables

58

148

173

Cash and cash equivalents

15,516

18,827

16,790

Total current assets

15,574

18,975

16,963

Total assets

15,579

54,972

16,971

 

 

 

 

Equity and liabilities

 

 

 

Equity attributable to owners of the parent

 

 

 

Share capital

20,261

20,261

20,261

Share premium

38,918

38,918

38,918

Other reserves

2,110

1,996

2,080

Retained deficit

(46,251)

(6,679)

(44,792)

Total equity

15,038

54,496

16,467

 

 

 

 

Non-current liabilities

 

 

 

Liability for share based payments

-

2

-

Total non-current liabilities

-

2

-

 

 

 

 

Current liabilities

 

 

 

Trade and other payables

541

474

504

Total current liabilities

541

474

504

Total liabilities

541

476

504

Total equity and liabilities

15,579

54,972

16,971

 

 

 

Consolidated Statement of Cash Flows

For the six months ended 30 September 2015

 

Unaudited

Unaudited

Audited

 

6 months to

30 September 2015

6 months to

30 September 2014

12 months to 31 March

 2015

 

US$'000

US$'000

US$'000

Cash flows from operating activities

 

 

 

Group operating loss for the period

(1,519)

(1,725)

(39,930)

Depreciation

3

3

6

Share based payment expense

30

74

129

Impairment of exploration and evaluation assets

308

-

36,593

Movements in working capital and other adjustments:

 

 

 

Decrease/(increase) in trade and other receivables

115

(72)

(97)

Increase/(decrease) in trade and other payables

37

(393)

(496)

Net cash flow used in operating activities

(1,026)

(2,113)

(3,795)

 

 

 

 

Cash flow from investing activities

 

 

 

Payments for property, plant and equipment

-

(1)

-

Expenditure on exploration and evaluation assets

(308)

(16,994)

(17,442)

Farm-in proceeds

-

20,410

20,410

Finance income

50

95

185

Net cash flow (used in)/from investing activities

(258)

3,510

3,153

 

 

 

 

Cash flow from financing activities

 

 

 

Net proceeds from issue of equity instruments

-

-

-

Net cash flow from financing activities

-

-

-

 

 

 

 

Exchange and other movements

10

2

4

 

 

 

 

Net change in cash and cash equivalents

(1,274)

1,399

(638)

Cash and cash equivalents at beginning of period

16,790

17,428

17,428

Cash and cash equivalents at end of period

15,516

18,827

16,790

 

 

Consolidated Statement of Changes in Equity
 

 

 

 

 

 

Share

capital

 

 

 

Share premium

 

 

Share based payment reserve

 

 

 

Merger reserve

 

Reverse asset acquisition reserve

 

 

 

Capital reserve

 

 

 

Retained deficit

 

 

 

 

Total

 

US$'000

US$'000

US$'000

US$'000

US$'000

US$'000

US$'000

US$'000

Balance at 1 April 2014

20,261

38,918

1,584

11,478

(11,256)

9

(5,051)

55,943

Loss and total comprehensive loss for the period

-

-

-

-

-

-

(1,628)

(1,628)

Share based payments

-

-

181

-

-

-

-

181

Balance at 30 September 2014 (Unaudited)

20,261

38,918

1,765

11,478

(11,256)

9

(6,679)

54,496

 

 

 

 

 

 

 

 

 

Balance at 1 October 2014

20,261

38,918

1,765

11,478

(11,256)

9

(6,679)

54,496

Loss and total comprehensive loss for the period

-

-

-

-

-

-

(38,113)

(38,113)

Share based payments

-

-

84

-

-

-

-

84

Balance at 31 March 2015

(Audited)

20,261

38,918

1,849

11,478

(11,256)

9

(44,792)

16,467

 

 

 

 

 

 

 

 

 

Balance at 1 April 2015

20,261

38,918

1,849

11,478

(11,256)

9

(44,792)

16,467

Loss and total comprehensive loss for the period

-

-

-

-

-

-

(1,459)

(1,459)

Share based payments

-

-

30

-

-

-

-

30

Balance at 30 September 2015 (Unaudited)

20,261

38,918

1,879

11,478

(11,256)

9

(46,251)

15,038

 

Company Information

 

1. General Information

Fastnet Equity plc ("Fastnet" or the "Company") is a company incorporated in England and Wales. Details of the registered office, the officers and advisers to the Company are presented on the Company Information page at the end of this report. The Company is listed on the AIM market of the London Stock Exchange (ticker: FAST) and the Enterprise Securities Market of the Irish Stock Exchange (ticker: FOI).

 

The principal activity of the Company during the period was oil and gas exploration. At a general meeting of the Company on 28 August 2015, a fundamental change of business and adoption of an Investing Policy was approved by the shareholders of the Company. The Investing Policy is to acquire companies or businesses in the healthcare sector particularly those in the biopharma sector.

 

The interim results of the Company for the six month period ended 30 September 2015 comprise the Company and its subsidiaries (together the "Group").

 

2. Basis of Preparation

The interim results have been prepared on the basis of the recognition and measurement requirements of International Financial Reporting Standards ("IFRS") as adopted by the European Union ("EU"), and their interpretations adopted by the International Accounting Standards Board ("IASB"). As is permitted by the AIM rules the Directors have not adopted the requirements of IAS34 "Interim Financial Reporting" in preparing the financial statements. Accordingly the financial statements are not in full compliance with IFRS and have neither been audited nor reviewed pursuant to guidance issued by the Auditing Practises Board. The accounting policies used in the preparation of the interim financial information are the same as those used in the Company's audited financial statements for the year ended 31 March 2015 and are expected to be used in the 31 March 2016 year-end financial statements.

 

The financial information for the six months ended 30 September 2014 and 30 September 2015 is unaudited. The financial information presented for the year ended 31 March 2015 is an extraction from the Group's audited accounts and therefore does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006 on which the auditors issued an unqualified report. The auditor's report also did not contain a statement under Section 498(2) or 498 (3) of the Companies Act 2006 and did not include reference to any matters the auditor drew attention by way of emphasis. The accounts for the year ended 31 March 2015 have been delivered to the Registrar of Companies. The Directors consider that the financial information presented in this Interim Report represents fairly the financial position, operations and cash flows for the period, in conformity with IFRS. The Interim Report for the six months ended 30 September 2015 was approved by the Directors on 21 December 2015.

 

Presentation of Balances

The Financial Statements are presented in US Dollars ("US$") which was the functional and presentational currency of the Company during the period and the functional currency of all the Group's subsidiary companies. Balances in the Financial Statements are rounded to the nearest thousand ("US$'000") except where otherwise indicated. In light of the Company's fundamental change in business the directors have reviewed the functional currency of Company and determined with effect from 1 November 2015 that Euro ("") will be the appropriate functional currency going forwards (see note 4.)

 

3. Loss per Share - Basic and Diluted

The Group presents basic and diluted loss per share ("LPS") data for its Ordinary Shares. Basic LPS is calculated by dividing the loss attributable to Ordinary Shareholders of the Company by the weighted average number of Ordinary Shares outstanding during the period. Diluted LPS is determined by adjusting the loss attributable to Ordinary Shareholders and the weighted average number of Ordinary Shares outstanding for the effects of all dilutive potential Ordinary Shares, which comprise warrants and share options granted by the Company.

 

The calculation of loss per share is based on the following:

 

6 months to 30 September 2015

6 months to 30 September 2014

12 months to 31 March 2015

Loss after tax attributable to equity holders of the parent (US$'000)

(1,459)

(1,628)

(39,741)

Weighted average number of Ordinary Shares in issue

345,369,071

345,369,071

345,369,071

Fully diluted average number of Ordinary Shares in issue

345,369,071

345,369,071

345,369,071

Basic and diluted loss per share (cent)

(0.42)

(0.47)

(11.51)

 

Where a loss has occurred, basic and diluted LPS are the same because the outstanding share options and warrants are anti-dilutive. Accordingly, diluted LPS equals the basic LPS.

 

The share options and warrants outstanding as at 30 September 2015 totalled 13,819,726 (31 March 2015: 20,397,423, 30 September 2014: 25,397,423) and are potentially dilutive.

 

4. Subsequent Events

Change of Functional and Presentational Currency

Following the companies fundamental change in business in August 2015 the Company will be funded in Pounds Sterling ("£"), alongside incurring costs in £, Euro ("€") and US$. Having considered the aggregate effect of all relevant factors, the Directors have concluded that € will be the appropriate functional currency of the Company with the change becoming effective from 1 November 2015. This reflects the fact that € is the predominant currency in the economic environment in which the Company operates and expects to operate in going forward. In line with IAS 21 when there is a change in an entity's functional currency the change should take place with effect from the date the Company determined that the characteristics required to identify the functional currency had changed. The Company determined that this change occurred during Q4 2015 and is effective for accounting purposes from 1 November 2015. The Group and Company will also adopt the € as the presentational currency going forward.

 

Demerger of Oil and Gas Assets

The Company's oil and gas subsidiaries were acquired by Fastnet Hydrocarbons Limited ("Fastnet Hydrocarbons"), on 17 December 2015 for an aggregate sum of £1. Fastnet Hydrocarbons is held in trust for the benefit of shareholders on the register of the Company as at the close of business on 16 December 2015. As a consequence the Group will no longer have any ongoing interest or further cost exposure in respect of oil and gas assets.

 

Prior to the demerger, as at 30 November 2015, the Company's cash balances amounted to €13.6m. As part of the demerger an unsecured four year term loan of €660,000 was granted to finance the residual running of oil and gas assets.

 

5. Copy of the Interim Report

Copies of the Interim Report are available to download from the Company's website at

www.fastnetequity.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FEFESSFISELE
Date   Source Headline
4th Mar 202112:00 pmRNSAmryt Announces Record FY 2020 Results
25th Feb 20217:00 amRNSAmryt Supports Global Rare Disease Day 2021
24th Feb 20217:00 amGNWAmryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
10th Feb 20217:00 amRNSAmryt to Present at SVB Leerink Conference
4th Feb 20217:00 amGNWAmryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
20th Jan 20217:00 amGNWAmryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6th Jan 20217:00 amRNSAmryt to present at H.C Wainwright Conference
23rd Dec 20207:00 amGNWAmryt Granted Orphan Drug Designation by the FDA for AP103
17th Dec 20207:00 amGNWAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11th Dec 202010:00 amGNWHolding(s) in Company
9th Dec 20202:45 pmGNWHolding(s) in Company
9th Dec 20207:00 amGNWAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
8th Dec 20207:00 amGNWAmryt Announces $40m Private Placement with Leading Biotech Investors
5th Nov 202012:00 pmGNWAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
29th Oct 20207:00 amGNWAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
19th Oct 20207:00 amGNWAmryt and Swixx Sign Distribution Deal for Lojuxta
14th Oct 20207:00 amRNSAMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020
14th Oct 20207:00 amGNWNotice of Results
12th Oct 202011:00 amGNWHolding(s) in Company
9th Oct 20207:00 amGNWVirtual Analyst & Investor Event - Tuesday November 3, 2020
8th Oct 20207:00 amGNWAMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020
1st Oct 20207:00 amGNWExercise of Options and Total Voting Rights
30th Sep 202012:30 pmGNWHolding(s) in Company
23rd Sep 20207:00 amRNSAMRYT SUPPORTS GLOBAL FH AWARENESS DAY
21st Sep 202011:00 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
15th Sep 20207:00 amRNSPOSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION
9th Sep 20202:05 pmRNSSecond Price Monitoring Extn
9th Sep 20202:00 pmRNSPrice Monitoring Extension
9th Sep 20207:00 amRNSPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
11th Aug 202011:09 amRNSCANCELLATION OF ADMISSION TO EURONEXT GROWTH
7th Aug 20207:00 amRNSAMRYT PRESENTING AT CANACCORD GENUITY CONFERENCE
6th Aug 202012:00 pmRNSAMRYT ANNOUNCES Q2 2020 RESULTS
29th Jul 20202:30 pmRNSResult of AGM
29th Jul 20207:00 amRNSAMRYT HOSTING KOL CALL ON EB DISEASE LANDSCAPE
20th Jul 20207:00 amRNSAMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
15th Jul 20208:00 amRNSEuronext Growth Dublin Notice
10th Jul 20207:00 amRNSExercise of Warrants & Issue of Ordinary Shares
8th Jul 20203:09 pmRNSAMRYT LISTED ON NASDAQ & CEO TO RING CLOSING BELL
30th Jun 20207:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
24th Jun 20207:00 amRNSForm F-1 publicly filed for impending US listing
4th Jun 20202:20 pmRNSDirector/PDMR Shareholding
3rd Jun 202011:30 amRNSDirector/PDMR Shareholding
3rd Jun 20207:00 amRNSAMRYT & SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA
11th May 20207:00 amRNSQ1 2020 RESULTS
11th May 20207:00 amRNSFY 2019 RESULTS
7th May 20209:00 amRNSNotice of Results
7th May 20207:00 amRNSFILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101
23rd Apr 20207:00 amRNSEASE CLINICAL STUDY UPDATE
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20207:00 amRNSMarket Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.